Financial Performance - The company's operating revenue for 2023 was CNY 447,583,620.32, representing a 1.07% increase compared to CNY 442,865,098.55 in 2022[25]. - The net profit attributable to shareholders decreased by 15.60% to CNY 77,039,439.15 from CNY 91,278,406.78 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 65,450,732.83, down 23.10% from CNY 85,112,132.04 in 2022[25]. - The cash flow from operating activities decreased significantly by 68.04% to CNY 37,030,989.82 from CNY 115,858,735.33 in 2022[25]. - Basic and diluted earnings per share fell by 32.14% to CNY 0.76 from CNY 1.12 in 2022[25]. - Total assets increased by 125.53% to CNY 1,469,967,974.01 at the end of 2023, compared to CNY 651,789,219.99 at the end of 2022[25]. - The net assets attributable to shareholders rose by 156.10% to CNY 1,331,040,247.54 from CNY 519,728,016.81 in 2022[25]. - The company achieved a revenue of 447.58 million yuan in 2023, representing a year-on-year growth of 1.07%[74]. - The net profit attributable to shareholders was 77.04 million yuan, a decrease of 15.60% compared to the previous year[75]. - Total assets increased to 1,469.97 million yuan, up 125.53% from the beginning of the period, primarily due to funds raised from the IPO[74]. Dividend Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 108,290,000 shares[4]. - The board of directors has approved a profit distribution plan, with no bonus shares to be issued[4]. - The total cash dividend distributed amounts to ¥32,487,000, representing 100% of the total profit distribution[196]. - The distributable profit as of December 31, 2023, is ¥265,529,817.49[196]. - The company prioritizes cash dividends when conditions allow, with a minimum cash distribution of 20% for companies in a growth phase with significant capital expenditures[191]. Market Position and Strategy - The company is focused on expanding its market presence and enhancing its product offerings through new product development and technology[4]. - The global pharmaceutical market is projected to reach USD 1.90 trillion by 2027, with a compound annual growth rate of 3%-6%[36]. - The Chinese pharmaceutical market is expected to reach CNY 31,945 billion by 2030, with a compound annual growth rate of 6.30% from 2019 to 2030[37]. - The company has established a strong market position in the raw material drug sector, benefiting from national centralized procurement policies[70]. - The company is actively pursuing an integrated development strategy of "raw materials + formulations" through acquisitions, such as the purchase of Lino Pharmaceutical[69]. Research and Development - The company focuses on R&D and innovation, increasing its R&D investment to enhance its technological capabilities, which are closely aligned with its core products and future development plans[41]. - The company is actively engaged in R&D for new products, with ongoing projects aimed at expanding its product portfolio[53]. - Research and development expenses increased by 30% to 150 million CNY, focusing on innovative drug formulations and delivery systems[172]. - The company plans to focus on the research and development of chemical raw materials in areas such as diabetes, anesthesia, cardiovascular, and mental health, while also expanding into digestive, hemostatic, analgesic, and anti-inflammatory fields[130]. Risk Management - The company emphasizes the importance of risk management and outlines potential risks and countermeasures in its future development outlook[4]. - The company faces risks related to changes in national policies, market supply and demand fluctuations, and rising upstream raw material prices, which could impact profit margins[133]. - The company is at risk of not passing consistency evaluations and winning national procurement bids for its main formulation products[136]. - The company will closely monitor exchange rate fluctuations and improve foreign exchange management to mitigate risks[137]. Governance and Management - The company has a complete and independent operational system, ensuring no reliance on its controlling shareholders[148]. - The company has conducted two shareholder meetings during the reporting period, with all resolutions passed legally and effectively[142]. - The company’s governance structure is sound, with a clear separation of powers among the board, supervisory board, and management[145]. - The company reported a leadership change with Jiang Hongsheng appointed as Chairman and General Manager in October 2023, following the retirement of previous executives[159]. - The company is in the process of appointing new directors and executives, including the election of Wu Bin as a director and Wang Jianwei as the new General Manager[159]. Financial Management - The company has established and effectively implemented internal control systems in compliance with regulatory requirements[198]. - There were no significant internal control deficiencies reported during the period[199]. - The company has received government subsidies related to income amounting to ¥3,992,164.91, which accounted for 5.01% of total profit[100]. - The company has not engaged in any derivative investments during the reporting period[117]. Employee Management - The total number of employees at the end of the reporting period is 624, with 480 in the parent company and 144 in major subsidiaries[186]. - The professional composition includes 325 production personnel, 54 sales personnel, 116 technical personnel, 15 financial personnel, 28 administrative personnel, and 86 others[186]. - Training programs are implemented to enhance employee skills in safety, environmental awareness, and quality, contributing to the company's high-quality development[189].
科源制药(301281) - 2023 Q4 - 年度财报